The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy

Wang, Fei; Zhou, Lei; Chen, Na; Li, Xiaoming

doi:10.1097/md.0000000000024664

Cited by 6 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…White adipose tissue serves as a reservoir for memory T cells, facilitating rapid response to exogenous stimuli [16,17]. Additionally, alterations in body composition have a negative impact on the activity of immune cells [18] Wang et al demonstrated that patients with a higher BMI have a well-developed immune system and can mobilize more immune cells [19]. In contrast, endstage tumor patients with wasting conditions (BMI < 18.5 kg/m²), mainly due to malnutrition or cachexia, exhibit suppressed immune cell activity, including CD8 + T and CD4 + T. [20] CD4 + T cells, also known as helper T cells, primarily secrete cytokines to regulate the function of other immune cells.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of body mass index on the efficacy of Sintilimab combined with SOX regimen for the first-line treatment of advanced inoperable gastric cancer

Yao,

Liu,

Pan

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: This study aims to investigate the predictive role of body mass index (BMI) on the efficacy of sintilimab combined with oxaliplatin + tiglio (SOX) in the first-line treatment for patients with advanced inoperable gastric cancer. Materials and methods: A retrospective analysis was conducted on 137 patients with advanced inoperable gastric cancer treated with sintilimab in conjunction with the SOX regimen at the Affiliated Hospital of Xuzhou Medical University from September 2020 to December 2023. Patients were categorized into the wasting group (BMI <18.5 kg/m²) and the non-wasting group (BMI ≥18.5 kg/m²) according to their BMI. There were 68 cases in the wasting group and 69 cases in the non-wasting group. Parameters including progression-free survival time (PFS), overall survival time (OS), objective remission rate (ORR), disease control rate (DCR), and adverse reactions were analyzed and compared between the two groups. Survival curves were plotted using the Kaplan–Meier method, and differences between the groups were assessed using the Log-rank test. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors affecting OS. A column-line diagram model was constructed based on the independent factors affecting patients' OS, and the model’s discriminative ability was evaluated using the C-index, ROC curve, and calibration curve. The clinical benefit of the column-line diagram was assessed using DCA curves. Results: Patients in the non-wasting group exhibited significantly longer median PFS compared to those in the wasting group (10.3 months vs 7.85 months, P=0.012) and significantly longer median OS(19.8 months vs 17.4 months, P<0.01). The ORR (29.0% vs 14.7%, P=0.043) and DCR (62.3% vs 44.9%, P=0.049) were significantly better in the non-wasting group compared to the wasting group. There was no significant difference in the overall incidence of adverse events between the two groups (73.5% vs 66.7%, P=0.381), and no grade >3 adverse reactions or adverse reaction-related deaths occurred in either group. Multifactorial analysis revealed distant metastasis (HR=0.24, 95% CI=0.11-0.52), tumor size (HR=2.17, 95% CI=1.04-4.53), and BMI (HR=0.39, 95% CI=0.17-0.87) as independent prognostic factors affecting OS (all P-values <0.05). Furthermore, the constructed column-line graphical model demonstrated good accuracy and discrimination (C-index for the training set: 0.790 (0.724–0.857), C-index for the validation set: 0.690 (0.579–0.801). Conclusion: BMI serves as a convenient, efficient, and clinically valuable predictor of the efficacy of sintilimab in combination with the SOX regimen for the first-line treatment of patients with advanced inoperable gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of body mass index on the efficacy of Sintilimab combined with SOX regimen for the first-line treatment of advanced inoperable gastric cancer

Yao,

Liu,

Pan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Thus, the outcomes of ICI therapy are invariably affected by obesity. In a cohort of 61 squamous cell carcinoma patients, Wang et al found a positive linear relationship between pre-treatment BMI and post-treatment blood immune cells, indicating a better response to immunotherapy in individuals with higher BMI ( 71 ). Better treatment response also correlated with better survival outcomes ( 71 ).…”

Section: Obesity and Therapeutic Survival Of Lung Cancermentioning

confidence: 99%

“…In a cohort of 61 squamous cell carcinoma patients, Wang et al found a positive linear relationship between pre-treatment BMI and post-treatment blood immune cells, indicating a better response to immunotherapy in individuals with higher BMI ( 71 ). Better treatment response also correlated with better survival outcomes ( 71 ). Many studies have found that higher BMI was significantly associated with better OS and PFS in patients treated with ICI ( 22 , 24 , 69 , 71 - 76 ) ( Table 4 ).…”

Section: Obesity and Therapeutic Survival Of Lung Cancermentioning

confidence: 99%

“…Better treatment response also correlated with better survival outcomes ( 71 ). Many studies have found that higher BMI was significantly associated with better OS and PFS in patients treated with ICI ( 22 , 24 , 69 , 71 - 76 ) ( Table 4 ). This association was strengthened for tumors expressing higher levels of PD-1/PD-L1 within the tumor microenvironment ( 21 , 22 , 69 , 71 , 89 ).…”

Section: Obesity and Therapeutic Survival Of Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Obesity and lung cancer—a narrative review

Vedire¹,

Kalvapudi²,

Yendamuri³

2023

J Thorac Dis

View full text Add to dashboard Cite

Background and Objective A highly nuanced relationship exists between obesity and lung cancer. The association between obesity and lung cancer risk/prognosis varies depending on age, gender, race, and the metric used to quantify adiposity. Increased body mass index (BMI) is counterintuitively associated with decreased lung cancer incidence and mortality, giving rise to the term ‘obesity paradox’. Potential explanations for this paradox are BMI being a poor measure of obesity, confounding by smoking and reverse causation. A literature search of this topic yields conflicting conclusions from various authors. We aim to clarify the relationship between various measures of obesity, lung cancer risk, and lung cancer prognosis. Methods The PubMed database was searched on 10 August 2022 to identify published research studies. Literature published in English between 2018 and 2022 were included. Sixty-nine publications were considered relevant, and their full text studied to collate information for this review. Key Content and Findings Lower lung cancer incidence and better prognosis was associated with increased BMI even after accounting for smoking and pre-clinical weight loss. Individuals with high BMI also responded better to treatment modalities such as immunotherapy compared to individuals with a normal BMI. However, these associations varied highly depending on age, gender, and race. Inability of BMI to measure body habitus is the main driver behind this variability. The use of anthropometric indicators and image-based techniques to quantify central obesity easily and accurately is on the rise. Increase in central adiposity is associated with increased incidence and poorer prognosis of lung cancer, contrasting BMI. Conclusions The obesity paradox may arise due to the improper use of BMI as a measure of body composition. Measures of central obesity better portray the deleterious effects of obesity and are more appropriate to be discussed when talking about lung cancer. The use of obesity metrics based on anthropometric measurements and imaging modalities has been shown to be feasible and practical. However, a lack of standardization makes it difficult to interpret the results of studies using these metrics. Further research must be done to understand the association between these obesity metrics and lung cancer.

show abstract

“…[16] Some studies have shown that the different compositions and locations of tumor immune cells are closely related to the prognosis of LSCC. [17,18] However, in past studies, researchers used traditional methods, such as immunohistochemistry, to explore the composition of immune cells in malignant tumor tissues. The number of cells that these methods can detect is very limited.…”

Section: Introductionmentioning

confidence: 99%

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

Dong

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most common forms of head and neck cancers. However, few studies have focused on the correlation between competing endogenous RNA (ceRNAs) and immune cells in LSCC.Methods: RNAseq expression of LSCC and adjacent tissues were downloaded from The Cancer Genome Atlas to establish a ceRNA network. The key gene in ceRNA was screened by the cox regression analysis to establish a prognostic risk assessment model. The CIBERSORT algorithm was then used to screen important tumor-infiltrating cells related to LSCC. Finally, co-expression analysis was applied to explore the relationship between key genes in the ceRNA network and tumor-infiltrating cells. The external datasets were used to validate critical biomarkers.Results: We constructed a prognostic risk assessment model of key genes in the ceRNA network. As it turned out, Kaplan-Meier survival analysis showed significant differences in overall survival rates between high-risk and low-risk groups (P < .001). The survival rate of the high-risk group was drastically lower than that of the low-risk group, and the AUC of 1 year, 3 years, and 5 years were all above 0.7. In addition, some immune infiltrating cells were also found to be related to LSCC. In the co-expression analysis, there is a negative correlation between plasma cells and TUBB3 (r = −0.33, P = .0013). External dataset validation also supports this result. Conclusion:In this study, we found that some key genes (SLC35C1, CLDN23, HOXB7, STC2, TMEM158, TNFRSF4, TUBB3) and immune cells (plasma cells) may correspond to the prognosis of LSCC.Abbreviations: ceRNA = competing endogenous RNA, DElncRNAs = differentially expressed lncRNAs, DEmRNAs = differentially expressed mRNAs, GEO = Gene Expression Omnibus, GO = Gene Ontology, HNSCC = head and neck squamous cell carcinoma, KEGG = Kyoto Encyclopedia of Genes and Genomes, LSCC = laryngeal squamous cell carcinoma, OS = overall survival, TCGA = The Cancer Genome Atlas.

show abstract

The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy

Cited by 6 publications

References 44 publications

Predictive value of body mass index on the efficacy of Sintilimab combined with SOX regimen for the first-line treatment of advanced inoperable gastric cancer

Predictive value of body mass index on the efficacy of Sintilimab combined with SOX regimen for the first-line treatment of advanced inoperable gastric cancer

Obesity and lung cancer—a narrative review

The analysis of tumor-infiltrating immune cell and ceRNA networks in laryngeal squamous cell carcinoma

Contact Info

Product

Resources

About